MAP1LC3A and colorectal carcinoma: After meticulous evaluation, only nine studies were identified to satisfy the inclusion criteria for further analysis [22, 24, 25, 29–34], including eight about “Beclin-1 and CRC” [24, 25, 29–34] and four about “LC-3 and CRC” [22, 24, 31, 32].